TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06088212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disease management program
Description: The components of our DMP include:~1. Intensive post-discharge education~2. Home surveillance of signs and symptoms will be reviewed (weekly in the first month and monthly thereafter) in a telehealth consultation with patient and/or carer.~3. Medical treatment involves a planned up-titration of cardioprotective medications that will proceed in the absence of advice from the general practitioner (GP) to the contrary. Close observation and frequent appointments are organised by the nurse with the patient's GP during up-titration period.~4. Exercise program delivered by an exercise physiologist~5. Maintenance phase of the DMP: During this maintenance phase, Intervention patients should have been fully transitioned to home care where they are managed by their GP at optimal doses of their medications. Repeated education and exercise guidance will continue with the carer, supported by our cardiac nurse and exercise physiologist via telehealth consultation bimonthly.
Study: NCT05397951

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicorder Pulse Wave Velocity Monitor
Description: The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vicorder Pulse Wave Velocity Monitor
Description: The pulse wave velocity monitor device will be placed on the right side of the neck and the right thigh and will provide measurements continuously throughout the experimental period.
Study: NCT03206814

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: POST-strategy
Description: Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
Study: NCT05135767

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing with Personalized Feedback
Description: A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Motivational Interviewing with Personalized Feedback
Description: A brief motivational interviewing (MI) intervention will target drinking. The intervention will leverage in-depth personalized feedback to identify areas of progress and barriers to change. The personalized feedback will include results of laboratory diagnostic tests, summary reports of timeline followback interviews, and graphical depictions of self-monitoring reports collected on smartphones in daily life. The brief intervention will include an initial 60-minute videoconference session, two brief, 5-10 minute phone-call check-ins completed one and two weeks after the initial intervention, and a 30-minute videoconference booster session completed three weeks after the initial intervention.
Study: NCT04976621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: BA is a brief behavioral treatment that helps people define goals, create and execute plans to attain them, and engage in meaningful activities. BA protocol components include: goal setting (especially for activities that promote social connectedness), creation of a plan (broken down into steps), strategies for implementation of steps, identification of potential barriers, tactics to overcome them, activity monitoring and scheduling, and emotion regulation strategies. The BA intervention will be delivered in 6 sessions over 3 months by Occupational Therapists trained in BA for post-TBI depression. BA sessions will be conducted in an office at the VA rehabilitation clinic or the home, depending on the veteran's preference.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment as Usual refers to usual care provided by the VA medical center.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Treatment as Usual refers to usual care provided by the VA medical center.
Study: NCT04845568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Experience
Description: The virtual reality experience includes psychoeducation content about healthy eating and consideration of future consequences. It includes a game where participants are in a go kart and pick up healthy or unhealthy foods on the road. Participants play in the present and in the future.
Study: NCT06269432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precision Antiplatelet Therapy Trial Group
Description: Use SPCM method to detect platelet aggregation function in patients, adjust antiplatelet drugs based on the test results, and receive precise antiplatelet treatment for 12 months. Non resistant patients with aspirin will continue to receive aspirin 100mg qd; Patients with aspirin resistance were given clopidogrel 75mg qd; Clopidogrel resistant patients were given ticagrelor 90mg bid.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Antiplatelet Therapy Control Group
Description: No adjustment of antiplatelet medication is required, and routine treatment with aspirin 100mg qd is given for 12 months.
Study: NCT05030987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal denervation in patients with HFpEF and uncontrolled hypertension

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham Treatment. After six months, cross-over is planned in all sham-treated patients and this patients will also receive a renal denervation.
Study: NCT05760339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted feeding
Description: Subjects in the will be instructed to follow a TRF regimen consisting of a daily 8h ad libitum eating period and 16h water fasting period during the last 2 weeks before surgery. Participants will be encouraged to begin their eating period at 08:00h and end it at 16:00h, since the metabolic benefits of TRF appear to be considerably more pronounced when the eating period starts early in the day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate loading
Description: Subjects will continue their usual diet and will receive two quantities of a clear beverage containing 12.5 g/100 mL maltodextrin (50 kCal/100 mL, pH 5.0); 800 mL at 22.00h on the evening before surgery and 400 mL two hours before anaesthesia induction.
Study: NCT04924543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online self-learning training module
Description: Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Online self-learning training module
Description: Training module in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refresher training
Description: Brief refresher training in optical diagnosis of IBD-associated dysplastic lesions during gastrointestinal endoscopy
Study: NCT06336954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adibelimab
Description: Adibelimab (1200mg, IV, every 3 weeks) combined with Famitinib (20mg, daily, orally) and Albumin-bound Paclitaxel (260mg/m2, Day 1, every 3 weeks)
Study: NCT06340399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCAA
Description: patients administering BCAA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: patient not administered BCAA
Description: patients not administered BCAA
Study: NCT04833699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rubber water bag
Description: bboiled tap water (80 °C) was put in a rubber water bag with a fluffy cover (Fig. 1), and placed on the patient's abdomen at 3, 6, 9, and 12 h after the surgical procedure for 30 minutes in addition to clinical standard postoperative care (ERAS protocol)
Study: NCT05720988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tagraxofusp-erzs
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tagraxofusp-erzs
Description: Given IV
Study: NCT05147961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Health
Description: Automated behavioral intervention via e-mail, web, and mobile phone

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Conventional recommendations on diet and exercise
Study: NCT06222385

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device measurements during overnight sleep and morning wake
Description: Overnight period and morning period device measurements

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Device measurements during overnight wake and morning sleep
Description: Overnight period and morning period device measurements
Study: NCT06033014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PM HeartIHD prediction
Description: The calculated prediction and the explainability factors will be made available to the physician, which the physician then can decide to take into his/hers evaluation about further treatment.
Study: NCT04869943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enobosarm
Description: Oral Enobosarm 9mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator (SERM)
Study: NCT04896112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNK01002
Description: LNK01002 will be administrated orally.
Study: NCT04507126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bacillus Calmette-Guerin (BCG)
Description: Vaccine
Study: NCT05478551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin
Description: We will be comparing botulinum toxin following the biopsies to placebo injection. We will then compare photos of each biopsy site at set intervals following the procedure.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline will serve as the placebo control on the contralateral side of the back.
Study: NCT06058169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sub Acute Whole Body Vibration Training
Description: Participants will be given a personal vibration plate (equipped with stabilizing bars) to take home for training which will last for up 12 weeks. For this test the participant will be asked to stand on a vibration plate for up to 20 minutes. Participants will be instructed to remove any footwear and stand mid-center on the platform in a standing position with feet shoulder width apart. The participant will be asked to step on and off of the vibration plate. During the first four weeks, participants will be asked to complete 5-10 minutes of WBV per day, at least 4-5 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 15 minutes and/or reduce the duration of rest. Beginning at week 9, based on how the participant feels, the study team may adjust the WBV time/duration up to 20 minutes per session, 4-5 days per week.
Study: NCT04977141

Intervention type: OTHER
Intervention: Decisional Conflict Scale
Description: Decisional Conflict Scale

Intervention type: OTHER
Intervention: Decisional Conflict Scale
Description: Decisional Conflict Scale
Study: NCT05835284

Intervention type: DEVICE
Intervention: Investigational Edge-on Silicon Photon Counting CT device
Description: Administration of IV contrast material, if applicable, shall be done according to the hospital's SOC. Administration of oral contrast material, if applicable, shall also be done according to the hospital's SOC. Images will then be compared with the previously acquired CT conducted as standard of care. The investigational scan will take approximately 60-120 minutes.
Study: NCT04969978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Academic Detailing
Description: * Group training of clinic staff prior to activation of the eReferral system and 12 months post-activation~* Follow-up booster sessions~* Monthly performance audit and feedback

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive overview of Quitline services and use of Quitline eReferral via online materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive overview of Quitline services and use of Quitline eReferral via online materials
Study: NCT05916118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Patients will be asked to engage in aerobic exercise using a pedal machine to move their arms and legs while in a seated position. Patients will be asked to exercise for a total of 30 minutes, which may be divided in up to three, ten-minute bouts of exercise.
Study: NCT04942730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m2/day iv x 6 days, days -7 through -2 of HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: 130 mg/m2 iv x 2 days, Days -7 through -6 of HSCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 1 mg/kg po qid x 3 days, Days -5 through -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg/kg iv x 2 days, Days +3 through +4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: 45 mg/kg/day, maximum 3 g/day, iv or po x 30 days, Days +5 through +35

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus 5Mg Cap
Description: 0.03 mg/kg/day iv or po, Days +5 through +100 with with further correction by concentration. Target concentration 5-15 ng/ml.
Study: NCT04651517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XACT ACE Robotics study arm
Description: Subjects will undergo lung procedures with the physician utilizing the XACT ACE Robotic System.
Study: NCT05631301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Circuits
Description: Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Circuits
Description: Weekly exercise circuits with a focus on strength, balance, cardiovascular fitness, and coordination

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Goal setting focused on the management of persistent post concussion symptoms, exercise, and engagement in daily activities

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation-Youth
Description: Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation-Youth
Description: Targeted educational sessions with a focus on the physical, cognitive, and psychological implications of persistent post-concussion symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation-Caregiver
Description: Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation-Caregiver
Description: Psychoeducational sessions focused on social support, in addition to addressing the implications of caring for youth experiencing persistent post concussion symptoms

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control Surveys
Description: Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control Surveys
Description: Surveys completed in week 1, and 8 for a subset of participants who are not involved in the study intervention to mirror study timeline and serve as control data for outcome measures assessed during experimental intervention
Study: NCT04698941

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin Paclitaxel
Description: Albumin Paclitaxel intravenous infusion was administered at a dose of 260 mg/m\^2 on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 20mg daily oral tablet taken.
Study: NCT05768633

Intervention type: BEHAVIORAL
Intervention: Counterfactual Inference Test
Description: All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.

Intervention type: BEHAVIORAL
Intervention: Counterfactual Inference Test
Description: All participants will be asked to complete the Counterfactual Inference Test - CIT (McNamara et al., 2003), a neuropsychological test that measures the ability to produce counterfactual-derived inferences. Moreover, the decision-making ability will be specifically tested through ad-hoc questionnaire (i.e., the Decision-Making Questionnaire). Finally, all participants will be screened with an extensive neuropsychological assessment, particularly on executive functioning.
Study: NCT04780022

Intervention type: OTHER
Intervention: Clinical events at last follow-up
Description: Clinical events (stroke, transient ischemic attack, peripheral embolism, deep venous thrombosis, atrial fibrillation, myocardial infarction, bleeding episode, death) at last follow-up
Study: NCT05064189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lacrimera
Description: A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.
Study: NCT05031403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitaton
Description: Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitaton
Description: Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitaton
Description: Patients will be asked to apply the rehabilitation program defined for them 3 days a week for 8 weeks. A training session will last approximately 45-60 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Exercise
Description: Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Exercise
Description: Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: Home Exercise
Description: Patients will be asked to apply the rehabilitation program for themselves with an exercise brochure. This therapy will last 3 days a week for 8 weeks.
Study: NCT06081023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psycho-educational weight reduction program
Description: This program provides behavioral technique in order to minimize level of emotional eating and level of obesity
Study: NCT05604638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase plus Tirofiban
Description: Patients will receive a continuous intravenous infusion of tirofiban at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tenecteplase plus Placebo
Description: Patients will receive a continuous intravenous infusion of Placebo at a rate of 0.1 µg/kg per minute for 26.5 h after start of tenecteplase treatment within 90 min